Research programme: anticancer radioimmunotherapeutics - Nordic Nanovector

Drug Profile

Research programme: anticancer radioimmunotherapeutics - Nordic Nanovector

Alternative Names: 177Lu-conjugated chimeric antibody (anti-CD37 ARC); 177Lu-conjugated humanized anti-CD37 antibody; 177Lu-NNV003; chHH1 - Nordic Nanovector; Humalutin; Lu-177 chimeric anti-CD37 antibody radionuclide conjugate - Nordic Nanovector; Lu-177-conjugated anti-CD37 chimeric HH1antibody - Nordic Nanovector

Latest Information Update: 25 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nordic Nanovector
  • Developer Nordic Nanovector; Norwegian Radium Hospital
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Immunostimulants; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Non-Hodgkin's lymphoma

Most Recent Events

  • 21 Apr 2018 Pharmacodynamics data from a preclinical trial in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 15 Mar 2018 Preclinical trials in Non-Hodgkin's lymphoma in Norway (Parenteral) before March 2018
  • 07 Jun 2017 Preclinical development is ongoing in Norway
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top